| Valuation method | Value, CHF | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 333.50 | -57 |
| Intrinsic value (DCF) | 697.29 | -11 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 367.30 | -53 |
Eli Lilly and Company (LLY.SW) is a global pharmaceutical leader headquartered in Indianapolis, Indiana, with a market capitalization of CHF 737.5 billion. Founded in 1876, the company specializes in discovering, developing, and marketing innovative human pharmaceuticals across multiple therapeutic areas, including diabetes, oncology, immunology, and neuroscience. Eli Lilly's flagship products include Trulicity and Jardiance for type 2 diabetes, Verzenio for breast cancer, and Taltz for autoimmune diseases. The company has a strong pipeline in metabolic disorders, oncology, and neurology, supported by strategic collaborations with biotech firms like Incyte, AbCellera, and Foghorn Therapeutics. Eli Lilly is listed on the Swiss Exchange (SIX) and maintains a robust financial position, with CHF 45 billion in annual revenue and CHF 10.6 billion in net income. Its diversified portfolio, strong R&D capabilities, and global commercial presence position it as a key player in the drug manufacturing sector.
Eli Lilly presents a compelling investment case due to its strong portfolio of blockbuster drugs, particularly in diabetes (Trulicity, Jardiance) and oncology (Verzenio). The company's revenue of CHF 45 billion and net income of CHF 10.6 billion reflect solid profitability, while its low beta (0.47) suggests defensive characteristics. However, risks include patent expirations, regulatory scrutiny, and competition in key therapeutic areas. The company's high debt (CHF 33.6 billion) could constrain financial flexibility, but its strong operating cash flow (CHF 8.8 billion) and dividend yield (~1.4%) provide stability. Investors should monitor pipeline progress, especially in Alzheimer's (donanemab) and obesity (tirzepatide), which could drive future growth.
Eli Lilly competes in the global pharmaceutical industry with a focus on high-growth therapeutic areas like diabetes, oncology, and immunology. Its competitive advantage lies in its strong R&D capabilities, evidenced by a robust pipeline and recent FDA approvals (e.g., Mounjaro for diabetes). The company's diabetes franchise, particularly GLP-1 agonists (Trulicity), competes directly with Novo Nordisk's Ozempic and Wegovy. In oncology, Verzenio competes with Pfizer's Ibrance and Novartis' Kisqali. Eli Lilly's immunology portfolio (Taltz) faces competition from AbbVie's Humira and Amgen's Enbrel. The company's strategic collaborations (e.g., with Incyte, AbCellera) enhance its biologics and oncology capabilities. However, its smaller market share in rare diseases and vaccines compared to peers like Pfizer and Roche is a relative weakness. Eli Lilly's scale and focus on innovative biologics position it well for long-term growth, but pricing pressures and biosimilar competition remain key challenges.